Gadoxetate Injectable Solution 0.25 mmol/mL Suppliers & Bulk Manufacturers

Available Forms: Injectable Solution

Available Strengths: 0.25 mmol/mL

Reference Brands: Eovist(US)

Category: Contrast Agent

Gadoxetate disodium 0.25 mmol/mL injection, a liver-specific gadolinium MRI contrast agent with a hepatobiliary imaging phase. For hospital radiology departments, imaging centres and importers.

Product Description:

Gadoxetate disodium, also called gadoxetic acid, is a liver-specific gadolinium-based MRI contrast agent. An ethoxybenzyl group lets hepatocytes take it up through membrane transporters, after which it passes into bile, while the rest is cleared by the kidneys, in roughly equal shares. It is a 0.25 mmol/mL solution for intravenous bolus injection, used at a lower gadolinium dose than standard extracellular agents, in vials or prefilled syringes for power injectors.

Radiologists use it to detect and characterise focal liver lesions. Dynamic images capture arterial and portal venous phases, and a hepatobiliary phase about 20 minutes later shows which lesions contain working hepatocytes. That helps tell focal nodular hyperplasia from adenoma or metastasis and supports staging of hepatocellular carcinoma; it also outlines the bile ducts. Although it is a linear agent, European regulators kept it for liver imaging when other linear agents were restricted over gadolinium retention. Renal function is screened because of nephrogenic systemic fibrosis risk in severe kidney disease.

Sourcing notes. Gadoxetate remains registered and in routine use in many markets, unlike older linear agents that have left them. Buyers are hospital radiology departments and imaging chains, often under annual tenders. Vials and syringes are kept at room temperature away from light, without a cold chain. Specify vial or prefilled syringe and fill volume, and confirm compatibility with your power injector. Ask for a CoA per batch with sterility, endotoxin and free gadolinium results, plus the GMP certificate and CoPP. It is a prescription-only diagnostic medicine, and most regulators expect a CTD dossier.